secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2023-01-20T23:59:59+00:00
Accession:  0001599298-23-000012
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 1.01, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit closes $500M licensing deal with Akeso for ivonescimab; authorized shares raised to 1B
--------------------------------------------------------------------------------

- Upfront payment $500M: $300M paid at close ($274.9M cash + 10M shares valued ~$25.1M); $200M due March 5, 2023.
- Akeso eligible for up to $4.5B milestones plus low double-digit royalties; Summit gets rights in US, Canada, Europe, Japan.
- Dr. Michelle Xia, Akeso CEO, appointed to Summit board.
- Authorized shares increased from 350M to 1B; rights offering up to $500M at discount.
- Summit ceases investments in Discuva platform; continues SMT-738 IND-enabling activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929823000012/0001599298-23-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929823000012/smmt-20230116.htm
  HTML page:      https://secwatch.observer/filing/0001599298-23-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer